Insider Selling: Medpace (NASDAQ:MEDP) CEO Sells $3,204,357.76 in Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 5,312 shares of the firm’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $603.23, for a total value of $3,204,357.76. Following the sale, the chief executive officer owned 919,290 shares of the company’s stock, valued at $554,543,306.70. This represents a 0.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Medpace Stock Performance

Shares of MEDP opened at $590.09 on Monday. Medpace Holdings, Inc. has a one year low of $250.05 and a one year high of $625.00. The stock has a 50-day moving average price of $539.39 and a 200 day moving average price of $424.46. The company has a market capitalization of $16.62 billion, a P/E ratio of 41.27, a P/E/G ratio of 2.67 and a beta of 1.42.

Medpace (NASDAQ:MEDP) last announced its earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.50 by $0.36. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The company had revenue of $659.90 million for the quarter, compared to analyst estimates of $640.49 million. During the same period in the prior year, the company posted $3.01 EPS. Medpace’s quarterly revenue was up 23.7% on a year-over-year basis. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. As a group, equities research analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Institutional Trading of Medpace

Large investors have recently modified their holdings of the company. Quent Capital LLC bought a new stake in shares of Medpace during the third quarter valued at about $25,000. Optiver Holding B.V. bought a new stake in shares of Medpace during the 3rd quarter worth about $27,000. Geneos Wealth Management Inc. lifted its stake in shares of Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after acquiring an additional 37 shares during the period. Brooklyn Investment Group boosted its holdings in shares of Medpace by 244.8% in the first quarter. Brooklyn Investment Group now owns 100 shares of the company’s stock valued at $30,000 after acquiring an additional 71 shares in the last quarter. Finally, Whittier Trust Co. boosted its holdings in shares of Medpace by 47.3% in the first quarter. Whittier Trust Co. now owns 109 shares of the company’s stock valued at $33,000 after acquiring an additional 35 shares in the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently weighed in on MEDP. Rothschild Redb downgraded shares of Medpace from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, September 3rd. Barclays boosted their price objective on Medpace from $425.00 to $485.00 and gave the company an “underweight” rating in a report on Friday, October 24th. UBS Group downgraded Medpace from a “neutral” rating to a “sell” rating and increased their target price for the stock from $300.00 to $305.00 in a report on Tuesday, July 29th. TD Cowen boosted their price target on Medpace from $356.00 to $462.00 and gave the company a “sell” rating in a report on Friday, October 24th. Finally, Jefferies Financial Group upped their price target on Medpace from $400.00 to $450.00 and gave the company a “hold” rating in a research report on Tuesday, September 9th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, ten have given a Hold rating and four have issued a Sell rating to the company. According to data from MarketBeat, Medpace currently has an average rating of “Hold” and an average price target of $487.18.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.